Abstract
Different coagulation assays, and even different reagents within an assay group, display variable effects at therapeutic concentrations of dabigatran. Some of these assay variations are of clinical importance, thus knowledge is needed for a correct interpretation of results.
Introduction
Oral anticoagulants are used world-wide to prevent thrombosis, for example in patients with atrial fibrillation, venous thrombosis and prosthetic heart valves. Despite their first use on humans in 1940, coumarins (Vitamin K antagonists, VKA) still are the only oral anticoagulants approved for antithrombotic treatment in atrial fibrillation and venous thrombosis. Millions of patients have been treated and the knowledge of pros and cons of this very efficient drug is well established, including effects on coagulation assays. One of the draw backs is the need for monitoring by measuring prothrombin time to achieve appropriate degree of anticoagulation. The inter-individual variation in weekly dosage is ten-fold, depending on many causes, for example intake of vitamin K with the food, polymorphisms in the liver enzymes degrading the drug and in the target enzyme VKORC1 (1) (2) . In recent years oral, reversible direct thrombin inhibitors have been developed. Practical advantages with these drugs are that the patients are given a fixed dose and that no monitoring is required.
The first to reach phase III clinical trials, ximelagatran, was not approved for clinical routine use due to side effects on the liver (3) (4) (5) . Ximelagatran is a prodrug, metabolised to the active inhibitor melagatran, in the patient. During the clinical trials some physicians were worried about increased INR found when measuring prothrombin time (outside the study protocol).
Therefore effects on prothrombin time assays by melagatran were studied and large differences between assays were found (6) . There are many reports on effects on coagulation assays by other thrombin inhibitors such as argatroban and lepirudin (7) (8) (9) (10) (11) (12) .
The new oral, reversible direct thrombin inhibitor dabigatran etexilate from BoehringerIngelheim is likewise a prodrug which is metabolised to its active form dabigatran by esterases. The drug is eliminated by the kidneys and a glomerular filtration rate below 30 mL/min is a contra-indication.
The drug is already approved for prevention of thrombosis in elective orthopaedic surgery based on successful clinical trials (13) (14) . The results from phase III clinical trials, RE-LY for prevention of thrombosis in atrial fibrillation and RE-COVER for treatment of venous thrombosis are very promising (15) (16) . We expect a wide-spread use of the drug in the near future, when approved by the medical agencies for treatment of patients with atrial fibrillation and venous thrombosis. Therefore it is important to know the effects of dabigatran on common coagulation assays not only in therapeutic concentration range but also above; since some patients with renal failure may accumulate the drug and non prescribed over-dosing may occur. Although there are few reports on effects on coagulation assays (17-18), we believe the coagulation laboratories need a more thorough knowledge, i.e. more coagulation analyses and different method principles and reagents, to avoid erroneous interpretation of results affected by analytical interferences. The aim of the present inter-laboratory study was to systematically investigate the effects on the most commonly used coagulation assays over a broad concentration range, including expected trough and maximum concentrations in patients on dabigatran 110 or 150 mg twice daily and in situations of over-dosage or accumulation. For practical and ethical reasons the study has been done utilizing plasma samples spiked with dabigatran.
Materials and Methods
Dabigatran (the active metabolite) was a gift from the manufacturer Boehringer-Ingelheim (Ingelheim, Germany). Blood collection tubes were from Becton Dickison (Franklin Lakes, NJ, USA).
Blood collection and addition of study drug
Human blood from 10 adult healthy volunteers, equal numbers of men and women, was 
Coagulation analyses
The following coagulation analyses were studied; Activated thromboplastin time (APTT), Table 1 .The effect on the APTT, as expressed as the concentration required to double the APTT (CT 2 ), was calculated to be between 227 -286 µg/L for the five different reagents (Table 1) , which is a relative difference of only 1.26-fold.
All PT-reagents were much less influenced than APTT, almost no samples were above the reference interval, i.e.> INR 1.2, at 100 µg/L (Figure 2) . However, the variation in sensitivities was substantial with SPA+ and Nycotest PT least sensitive and the only studied Quick PT reagent Innovin most sensitive ( Table 2) . Even at the highest tested concentration, which is lower than found for elderly (21) . Plasma concentrations are very dependent on renal function in different populations (22) . In the RE-LY study on prevention of thrombosis in atrial fibrillation two doses were tested, 110 and 150 mg, twice daily (15) . In the RE-COVER study on treatment of venous thrombosis one regimen was used, 150 mg twice daily (16) . The concentrations used in our tables have been based on assumed trough and maximum concentrations in patients on dabigatran 150 mg twice daily.
In this study we have used plasma samples spiked with dabigatran in a very broad concentration range and common coagulation assays including several reagents in order to generate useable knowledge for the laboratories. A limitation of our study is the use of spiked plasma samples. However, it is unjustifiable to deliberately expose patients to potentially toxic doses and untenable to collect such samples from patients. Furthermore, dabigatran is the active compound (18, 23) converted in vivo from dabigatran etexilate by esterases and is mainly excreted as such through the kidneys, thus for dabigatran spiked samples is a valid methodology. About 20% of dabigatran gets conjugated by glururonosyltransferases to pharmacologically fully active glucuronide conjugates and is secreted in that form (18, 23) .
Hepatic impairment had only small effects on bioconversion of dabigatran etexilate to the active compound (20) .
Our results for APTT are in accordance with results previously reported by Stangier et al. at
Boehringer-Ingelheim (17-18, 22, 24-25) . Almost all patients will be expected to have prolonged APTT at C max and a large proportion even at trough concentration irrespective of reagent used at the laboratory.
For PT-assays the dilution of the sample is important since dabigatran is a reversible inhibitor and the effect on PT will decrease with increasing dilution. Our findings are in accordance with previous results on the thrombin inhibitor melagatran (6), i.e. the Quick PT reagent with final plasma dilution 1:3 was affected more than all Owren methods with final dilution 1:21.
The reason is not clear why some Owren PT reagents are more sensitive than others despite the fact that all are combined rabbit thromboplastins, even considerably more so than the APTT-reagents. For point of care instruments with no sample dilution an even stronger effect is anticipated, which has been shown previously for melagatran (6) . Dabigatran caused interference in the studied methods for APC resistance increasing the ratio, which may could lead to misclassification, making patients heterozygous for factor V Leiden appear normal. However, studies on more APC-resistant donors are needed to confirm this observation. Furthermore, most laboratories nowadays use DNA-analysis to diagnose APCresistance, i.e. factor V Leiden, and not functional methods. It is not surprising that Pefakit APC-R which is based on prothrombinase activation is affected more by a thrombin inhibitor than Coatest APC Resistance V which is based on APTT. For factor Xa inhibitors the reverse would be expected.
Our conclusion is that dabigatran may have clinically significant, reagent dependent effects on common coagulation analyses. Furthermore thrombophilia investigation should not be done on patients while on dabigatran without knowledge of how the drug affects the locally used methods. 
